What is he best known for?
The fields of study he is best known for:
- Gene
- Immune system
- Cancer
Carlo Heirman mainly investigates Antigen, Dendritic cell, Cytotoxic T cell, Immunology and Antigen presentation.
His Antigen study combines topics from a wide range of disciplines, such as Cancer research, Immune system, CD40 and Cancer immunotherapy.
Carlo Heirman interconnects T cell and Cell biology in the investigation of issues within Dendritic cell.
He is interested in Antigen-presenting cell, which is a field of Cytotoxic T cell.
His biological study spans a wide range of topics, including Interleukin 12 and Melanoma.
His Antigen presentation research incorporates themes from Epitope, Molecular biology and Electroporation.
His most cited work include:
- CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. (953 citations)
- Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation (299 citations)
- Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. (172 citations)
What are the main themes of his work throughout his whole career to date?
Carlo Heirman mainly focuses on Immunology, Antigen, Immunotherapy, Dendritic cell and Cytotoxic T cell.
His research integrates issues of Cancer research, Electroporation, Antigen presentation and Cancer immunotherapy in his study of Antigen.
His study on Dendritic cell is mostly dedicated to connecting different topics, such as Cell biology.
In his work, RNA and Bioinformatics is strongly intertwined with Messenger RNA, which is a subfield of Cell biology.
His Cytotoxic T cell research incorporates elements of Molecular biology, Cytokine secretion and Interferon.
His CD8 study combines topics in areas such as Epitope, T cell, Priming and Virology.
He most often published in these fields:
- Immunology (40.32%)
- Antigen (37.10%)
- Immunotherapy (31.45%)
What were the highlights of his more recent work (between 2013-2020)?
- Cancer research (25.00%)
- Immunotherapy (31.45%)
- Immune system (24.19%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Cancer research, Immunotherapy, Immune system, Immunology and Messenger RNA.
His study in Immunotherapy is interdisciplinary in nature, drawing from both Dendritic cell, Antigen and Transfection.
His Antigen study combines topics from a wide range of disciplines, such as Virus and Adjuvant.
His work carried out in the field of Immune system brings together such families of science as Immunogen and Vaccination.
His Immunology research includes elements of Cytotoxic T cell, Transplantation and Virology.
His Messenger RNA research incorporates themes from RNA, Melanoma, Electroporation and Cell biology.
Between 2013 and 2020, his most popular works were:
- Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma (138 citations)
- mRNA-based dendritic cell vaccines (66 citations)
- Gain of 20q11.21 in human embryonic stem cells improves cell-survival by increased expression of Bcl-xL (62 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Immune system
- Cancer
His primary areas of investigation include Immunology, Immunotherapy, Dendritic cell, Cytotoxic T cell and T cell.
His research on Immunology often connects related topics like Pharmacology.
His Dendritic cell research is multidisciplinary, incorporating perspectives in Messenger RNA and Immunity.
His studies in Antigen-presenting cell and Antigen presentation are all subfields of Cytotoxic T cell research.
His T cell research is multidisciplinary, incorporating elements of CD8, Antigen, CD40 and Cell biology.
His studies deal with areas such as Interferon and Cancer research as well as Antigen.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
